Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (T SCM ), a key differentiator for Poseida’s CAR-T programs  SAN DIEGO , Sept.